ALZAMEND NEURO INC (ALZN) Stock News
NASDAQ:ALZN - Nasdaq - US02262M5067 - Common Stock - Currency: USD
ALZN Latest News, Press Relases and Analysis
Which stocks are experiencing notable movement on Friday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Top movers in Friday's session
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
Capital Raised to Support Five Clinical Trials
Traders are paying attention to the gapping stocks in Friday's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
Let's take a look at the stocks that are in motion in today's session.
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled
AL001 has the potential to provide the benefits of marketed lithium salts while mitigating currently experienced toxicities associated with lithium.
Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone
Alzamend Neuro shares surged after dosing the first patient in its AL001 Phase II trial. This novel lithium formulation aims for improved brain delivery and fewer side effects.
Keep an eye on the top gainers and losers in Thursday's session.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
The market is filled with gapping stocks in Thursday's session.
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
What's going on in today's pre-market session
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Booking CFO leans on AI in push to run ‘tight ship’
The online travel company is looking to slash costs by as much as $450 million by the end of 2027. It aims to reinvest some of the freed-up capital into AI projects.
Why Nintendo Stock Is Jumping Today
Nintendo (OTC: NTDOY) stock is posting gains in Tuesday's trading. The stock market rallied early in today's trading following news that the Trump administration had started preliminary tariff negotiations with Japan and other countries. While the relief rally for the broader market faded, the news of trade negotiations with Japan is powering gains for Nintendo stock.
Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?
We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look at where Alzamend Neuro, Inc. (NASDAQ:ALZN) stands against other cheapest stocks insiders are buying in March. After solid gains Monday, the broader market index and blue chip companies traded flat Tuesday, […]
Mentions: COMP
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Alzheimer’s subjects
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure...
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for Next-Gen Lithium Treatment of Major Depressive Disorder at Mass. General Hospital...
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in PTSD subjects
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Bipolar Disorder subjects
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder at Massachusetts General Hospital...
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy human subjects
